TP53 mutations in Romanian patients with colorectal cancer

• Published in: Genes and environment Vol. 45; no. 1; pp. 20 - 8
• Main Authors: Manirakiza, Felix, Yamada, Hidetaka, Iwashita, Yuji, Ishino, Keiko, Ishikawa, Rei, Kovacs, Zsolt, Osvath, Eva, Nzitakera, Augustin, Gurzu, Simona, Sugimura, Haruhiko
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 01.07.2023; BioMed Central; BMC
• Subjects: Amino acids; Analysis; Cancer; Cancer patients; Carcinogenesis; Carcinogens; Cell cycle; Colorectal cancer; Colorectal carcinoma; Deoxyribonucleic acid; Developing countries; Diet; DNA; DNA damage; DNA sequencing; Frameshift mutation; Gene deletion; Gene sequencing; Genetic aspects; Genetic research; Genome; Genomes; Genomics; Health aspects; LDCs; Lung cancer; Missense mutation; Mortality; mRNA turnover; Mutation; Nonsense-mediated mRNA decay; Novel mutation; Nucleotide sequencing; p53 Protein; Paraffin; Population studies; Proteins; RNA; Romania; Substitutes; TP53; Transversion; Tumor proteins; Tumor suppressor; Whole genome sequencing; Romania; Romania; Environment; Genome; Life style in East Europe; TP53; Tumor suppressor; Cancer; Novel mutation
• ISSN: 1880-7062; 1880-7046; 1880-7062
• DOI: 10.1186/s41021-023-00277-2

Colorectal cancer (CRC) has been ranked as the second most deadly cancer and the third most diagnosed cancer cases for the year 2020. Specifically for Romania, the number of CRC-related deaths in 2019 was estimated at 6307 people, with a standardized mortality rate of 33.8 per 100,000 inhabitants. Although the tumor protein 53 (TP53) gene is intensively studied, there are few data on TP53 mutations in Romanian CRC. Furthermore, since genetic alterations may show geographical differences, our study aimed to analyze the clinical status and TP53 somatic variation in Romanian CRC patients. DNA from 40 randomly selected cases of CRC was extracted from formalin-fixed paraffin-embedded tissues and sequenced using direct Sanger sequencing techniques, and variants were annotated according to the recommendations of the Human Genome Variation Society. Novel variants were analyzed using MutationTaster2021 to predict their effects. The mean age was 63.6 years (range 33-85 years) with a male to female ratio of 2.3. More than 45% (18/40) had an advanced cancer stage (≥ stage III). Mutations were found in 21/40 cases (52.5%), with one case having two mutations, giving a total of twenty-two mutations in the TP53 coding DNA. These mutations include 3 (13.6%) insertion-deletion mutations, two of which are novel frameshift mutations: c.165delT (in exon 4) and c.928_935dup (in exon 9), both of which are predicted to lead to nonsense-mediated mRNA decay and are classified as deleterious. The remaining 19 (86.36%) were substitution mutations: 1 nonsense and 18 (81.8%) missense mutations, with G > A (n = 7/19; 36.8%) and C > T (n = 6/19; 31.5%) transitions being the most common. The G > T transversion was found in 21.05% (4/19) of the substitution mutations. We have described two novel frameshift mutations in TP53. The discovery of novel mutations following the efforts of The Cancer Genome Atlas and other large-scale cancer genome sequencing projects may be further evidence of the heterogeneous nature of mutations in cancer and may indicate that the identification of carcinogenic mutations is not yet saturated. Further sequencing is therefore needed, especially in less studied populations. Importantly, consideration of their geographical environment will shed light on population-specific carcinogenesis.